KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Neogenomics (NEO) over the last 15 years, with Sep 2025 value amounting to $51.3 million.

  • Neogenomics' Accumulated Expenses fell 1.66% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year decrease of 1.66%. This contributed to the annual value of $62.4 million for FY2024, which is 17.46% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Accumulated Expenses is $51.3 million, which was up 5.65% from $48.6 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Accumulated Expenses registered a high of $62.4 million during Q4 2024, and its lowest value of $23.6 million during Q1 2021.
  • For the 3-year period, Neogenomics' Accumulated Expenses averaged around $47.2 million, with its median value being $48.6 million (2025).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first spiked by 75.48% in 2021, then fell by 4.57% in 2025.
  • Neogenomics' Accumulated Expenses (Quarterly) stood at $38.3 million in 2021, then climbed by 4.80% to $40.1 million in 2022, then soared by 32.44% to $53.2 million in 2023, then rose by 17.46% to $62.4 million in 2024, then declined by 1.66% to $51.3 million in 2025.
  • Its Accumulated Expenses stands at $51.3 million for Q3 2025, versus $48.6 million for Q2 2025 and $39.5 million for Q1 2025.